Citizens Jmp Initiates Coverage on Bicara Therapeutics (NASDAQ:BCAX)

Analysts at Citizens Jmp initiated coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research note issued on Thursday, Marketbeat reports. The brokerage set a “market perform” rating and a $31.00 price target on the stock. Citizens Jmp’s price target suggests a potential upside of 84.52% from the company’s previous close.

Several other research analysts have also recently issued reports on the stock. Wells Fargo & Company increased their price target on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Citigroup started coverage on Bicara Therapeutics in a report on Thursday. They issued an “outperform” rating for the company. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Finally, BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bicara Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $28.33.

Bicara Therapeutics Price Performance

Bicara Therapeutics stock opened at $16.80 on Thursday. The business has a 50 day simple moving average of $17.52 and a 200-day simple moving average of $14.89. Bicara Therapeutics has a 12 month low of $7.80 and a 12 month high of $19.71. The stock has a market capitalization of $920.34 million, a PE ratio of -7.50 and a beta of -0.79.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.12). As a group, equities research analysts anticipate that Bicara Therapeutics will post -2.59 EPS for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other news, CFO Ivan Hyep sold 1,882 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $18.15, for a total value of $34,158.30. Following the sale, the chief financial officer directly owned 145,355 shares in the company, valued at $2,638,193.25. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Ryan Cohlhepp sold 3,828 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $18.10, for a total transaction of $69,286.80. Following the transaction, the chief operating officer directly owned 210,164 shares of the company’s stock, valued at approximately $3,803,968.40. This trade represents a 1.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 95,922 shares of company stock worth $1,784,142 over the last ninety days. 15.50% of the stock is currently owned by company insiders.

Institutional Trading of Bicara Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. UBS Group AG boosted its stake in shares of Bicara Therapeutics by 97.4% during the fourth quarter. UBS Group AG now owns 192,191 shares of the company’s stock valued at $3,235,000 after acquiring an additional 94,829 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Bicara Therapeutics in the 4th quarter valued at about $150,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Bicara Therapeutics during the 4th quarter worth about $45,000. SG Americas Securities LLC acquired a new stake in shares of Bicara Therapeutics during the 4th quarter worth about $187,000. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Bicara Therapeutics in the third quarter valued at approximately $296,000.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.